Qiagen Plans Non-US Offering of Convertible Notes to Raise up to $300M | GenomeWeb

NEW YORK (GenomeWeb News) – Qiagen today announced plans to issue convertible notes in a private placement to raise up to $300 million in net proceeds.

The company also plans to buy back convertible notes due in 2026.

Qiagen said that it plans to repurchase up to the full $300 million of its outstanding 2026 convertible notes from non-US holders. It will use cash for the purchase, which will be priced based partly on today's variations in Qiagen's stock price.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.